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Objectives: The aim was to investigate if offering symptomatic therapy (Uva-ursi or ibuprofen) alongside
a delayed prescription would relieve symptoms and reduce the consumption of antibiotics for adult
women presenting with acute uncomplicated urinary tract infection (UTI).
Methods: A 2  2 factorial placebo controlled randomized trial in primary care. The participants were
382 women aged 18e70 years with symptoms of dysuria, urgency, or frequency of urination and sus-
pected by a clinician to have a lower UTI. The interventions were Uva-ursi extract and/or ibuprofen
advice. All women were provided with a delayed or ‘back-up’ prescription for antibiotics. Missing data
were imputed using multiple imputation methods (ISRCTN registry: ISRCTN43397016).
Results: An ITT analysis of mean score for frequency symptoms assessed on Days 2e4 found no evidence
of a difference between Uva-ursi vs. placebo e0.06 (95% CI e0.33 to 0.21; p 0.661), nor ibuprofen vs. no
ibuprofen advice e0.01 (95% CI e0.27 to 0.26; p 0.951). There was no evidence of a reduction in anti-
biotic consumption with Uva-ursi (39.9% vs. placebo 47.4%; logistic regression odds ratio (OR) 0.59 (95%
CI 0.22e1.58; p 0.293) but there was a signiﬁcant reduction for ibuprofen advice (34.9% vs. no advice
51.0%; OR 0.27 (95% CI 0.10 to 0.72; p 0.009). There were no safety concerns and no episodes of upper
tract infection were recorded.
Conclusions: We found no evidence of an effect of either intervention on the severity of frequency
symptoms. There is evidence that advice to take ibuprofen will reduce antibiotic consumption without
increasing complications. For every seven women given this advice, one less will use antibiotics.
M. Moore, Clin Microbiol Infect 2019;25:973
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute cystitis is one of themost frequent triggers of consultation
in women in primary care. The lifetime risk in women is 50% andnd Population Science, Uni-
moor Health Centre, South-
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).the annual incidence is over 10% [1]. It accounts for between 1% and
3% of consultations and results in an antibiotic prescription for the
majority of women (93%) [2]. A meta-analysis of ﬁve randomized
trials of antibiotic/placebo conﬁrmed greater symptomatic and
bacteriological cure with antibiotic treatment but with only a
modest effect on duration of symptoms [3]. Many women pre-
senting with symptoms of urinary infection will not have a bacte-
riologically proven infection on culture [4] and most complaints
will be self-limiting [5]. However, while women are open toof Clinical Microbiology and Infectious Diseases. This is an open access article under
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treatment would require an appropriate approach to dealing with
the burden of symptoms and responding to women's suffering by
offering alternative symptomatic treatments [6,7].
Two alternative treatments for symptomatic relief have been
identiﬁed, namely ibuprofen and Arctostaphylos uva-ursi (L.)
Spreng. (Ericaceae) leaf extract, a plant found in the mountains of
the Northern Hemisphere with a long history of use in western
herbal medicine, hereafter abbreviated to “Uva-ursi” [8]. The evi-
dence suggests that NSAIDs may provide symptom relief and
reduce antibiotic use, but there is also suggestive evidence that
they may increase subsequent upper tract infections [9e11]. Uva-
ursi was not tested in randomized trials [8]. We proposed to test
whether offering these symptomatic therapies alongside a delayed
prescription would provide symptomatic relief and reduce the
consumption of antibiotics.
Methods
The methods are described in full elsewhere [8]. ATAFUTI is a
multicentre, factorial (2  2) design, including a randomized
double-blind placebo-controlled trial of Uva-ursi, and open prag-
matic trial of advice/no advice to take ibuprofen. Recruitment took
place in primary care settings across the UK.
Treatments were allocated at random by prior randomization of
treatment packs using block randomization, with no stratiﬁcation
factors, into one of four groups:
 Group 1 Uva-ursi þ advice to take ibuprofen
 Group 2 Placebo þ advice to take ibuprofen
 Group 3 Uva-ursi þ no advice to take ibuprofen
 Group 4 Placebo þ no advice to take ibuprofen.
We recruited adult women presenting with symptoms of non-
complicated acute UTI. Consenting participants were asked to
provide a urine specimen for bacterial analysis at baseline, were
asked to take the study medication for 3e5 days and to complete a
symptom diary for up to 2 weeks. All participants were issued a
prescription for antibiotics to be delayed and used if symptoms
worsened, or after 3e5 days if symptoms failed to improve. A GP
notes review was completed after 3 months to record re-
consultations with further urinary symptoms.
Patient public involvement
Two patients/public representatives were involved in the study
design and development of the study materials, attended trial
steering group meetings, and helped with interpretation of the
results.
Participants' eligibility
Inclusion
Women (aged 18e70 years) who upon presenting to primary
care with dysuria, urgency, or frequency of urination were sus-
pected by a GP or nurse practitioner to have a lower urinary tract
infection.
Exclusions
Criteria for exclusion were known or suspected pregnancy;
breast feeding; suspected upper urinary tract infection (presenting
with back pain, fever >38C, systemic illness); patients requiring
immediate antibiotics; are within 7 days of taking antibiotics;
frequent recurrent UTI (>3 UTI episodes in past 12 months); known
contraindications or cautions to ibuprofen; using an NSAID ortaking an Uva-ursi preparation and unwilling or unable to discon-
tinue for the study period; diabetes; an immunodeﬁciency state or
on long-term corticosteroids or chemotherapy; bladder surgery
including cystoscopy in the last 4 weeks; currently taking warfarin,
or a defect of the blood clotting system; recruited to another trial in
the previous 4 weeks.
Participants and clinicians were blinded to the Uva-ursi groups.
Recruiting practitioners were blinded to the ibuprofen recom-
mendation prior to opening the pack, and endorsed ibuprofen use
only when directed after opening. Outcome assessors were blind to
allocation. The randomization sequence was generated by the
study statistician and communicated to the manufacturer of the
study medication.
Study interventions
The investigational medicinal product comprised Uva-ursi
extract containing 20% arbutin with a matching placebo contain-
ing sugar beet ﬁbre (Fibrex®), an inert substance with a similar
colour, and a herbal ﬂavour. The total daily dose of Uva-ursi was
3600mgwhichwas divided across three capsules to be taken orally
three times a day (Table S1 for details of herbal intervention).
Participants were asked to take the study medication between 3
and 5 days (stopping if symptoms had improved). A prescription for
back-up antibiotics was provided to participants with instructions
to take if adequate symptom relief was not obtained from the study
medication.
A structured advice sheet and card detailing the ibuprofen dose
was provided to participants randomized to the ibuprofen arm. A
daily dose of 1200mg, tomatch the dose used in the previous trials,
was recommended or prescribed on request [9,12].
Assessment and follow-up
Participants were requested to complete a daily symptom diary
used in previous studies of UTI detailing severity of their urinary
tract symptom(s) [4,13,14]. The diary scale recorded symptom
severity on a seven-point scale ranging from 0 to 6; 0¼ no problem,
1 ¼ very little problem, 2 ¼ slight problem, 3 ¼moderate problem,
4 ¼ bad problem, 5 ¼ very bad problem, and 6 ¼ as bad as it could
be). Participants were contacted by telephone after 3 days to assist
completion and in the event of delayed return of the diary, to
prompt return or to complete a brief symptom inventory.
Primary outcome
Mean frequency symptom severity score on Days 2e4 using 14-
day validated diary data [4,13e15]. This is deﬁned as themean score
of the frequency symptoms (burning, urgency, daytime frequency,
and night time frequency), recorded on Days 2, 3, and 4.
Secondary outcomes
The secondary symptoms included mean unwell symptom
severity score on Days 2e4, duration of moderately bad or worse
symptoms, and mean global symptom severity score using 14-day
validated diary data [4,13e15]. Use of antibiotics and re-
consultation (full details in web supplement).
Exploratory analysis
Differential effects on primary outcome depending on culture
conﬁrmation of urinary tract infection were aligned to European
standards [16]. Infection was deﬁned as any growth of bacteria in
the urine culture results.
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In our previous study the severity of frequency symptoms at
2e4 days was 2.15 (SD 1.18) in the immediate antibiotic group and
2.11 (mean difference e0.04 95% CI e0.47 to 0.40) in the delayed
antibiotic group [13], based on severity of frequency symptoms inFig. 1. Patient ﬂowthe delayed antibiotic group [13] and the clinically signiﬁcant
change in symptom severity of 0.5. For the 2  2 factorial design, to
detect a mean severity difference of 0.5 with SD 1.18 required a
sample of 60 per group. We further increased the sample size to
take into account the numbers needed to demonstrate a reduction
in antibiotic use, a key secondary outcome, and hence the initialin the study.
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nation please see supplementary material). We noted the loss to
follow-up was higher than anticipated and amended the required
sample to 376 patients (94 per group). The trial was not powered
for any interaction between factorial groups.
Statistical analysis
Owing to missing data, for the primary endpoint analysis and
some key secondary endpoint analyses, a hierarchical manual
imputation process was ﬁrst carried out on any missing symptom
severity values on days either side. After the manual imputation
process, multiple imputation was performed.
For the primary outcome, analysis of covariance was used to
analyse the imputed mean frequency symptom severity data on
Days 2e4 adjusting for the baseline symptom severity score and
age. This analysis was repeated adjusting also for the use of anti-
biotics. Logistic regression was used for dichotomous outcomes
(antibiotic use, re-consultation in 1 month with UTI, and re-
consultation within 3 months with UTI from notes review)
adjusting for age on records with complete data. Negative binomial
regression was used to analyse duration of moderately bad symp-
toms adjusting for age, performed on records with complete data,
as stipulated in the pre-speciﬁed analysis plan.
All analyses were also carried out on a per-protocol basis in
accordance with patients' compliance with Uva-ursi and ibuprofen.
Results
Recruitment is detailed in Fig. 1. Participants were well matched
at baseline (Table 1). Withdrawal data are shown in Table 2. After
telephone contact, 248 of the returned diaries contained sufﬁcient
information for the complete case primary endpoint analysis (248/
382; 65%). The primary endpoint analysis of covariance of fre-
quency symptom severity on Days 2e4, adjusting for baseline fre-
quency symptom severity, incorporating multiple imputed data
(ITT population B, n ¼ 382), gave no evidence of a difference in
symptom severity between the factorial groups (Table 3): Uva-ursi
e0.06 (95% CI e0.33 to 021; p 0.661); ibuprofen advice e0.01 (95%
CI e0.27 to 0.26; p 0.951). Similarly when controlling for antibiotic
use up to day 4, no differences were seen (Table 4). WhenTable 1
Baseline table.
Characteristic Group 1a
(Uva-ursi þ Ibuprofen
advice) (n ¼ 102)
Group 2a
(Placebo þ ibu
advice) (n ¼ 86
Age in years at baseline, mean (SD) 45.5 (15.16) 39.9 (15.48)
Symptom duration in daysb, median (IQR) 3.0 (2.0 to 5.0) 3.5 (2.0 to 6.0)
Patient's temperature, C, mean (SD) 36.7 (0.45) 36.7 (0.50)
Urine culture infected, n (%) 19 (24.1%) 26 (37.7%)
Experience of a urine infection in the last
year, n (%)
30 (53.6%) 30 (58.8%)
Frequency symptomsc, n, mean (SD)
All patients 102, 2.5 (1.23) 86, 2.6 (1.14)
Patients with symptom diary return
information available
59, 2.4 (1.20) 53, 2.5 (1.00)
Patients without symptom diary return
information available
43, 2.6 (1.26) 33, 2.7 (1.34)
IQR, inter-quartile range; SD, standard deviation; MSU, midstream specimen of urine.
a Group 1¼ Patients who received Uva-ursi and advice to take ibuprofen, Group 2¼ Pat
who received Uva-ursi and no advice to take ibuprofen, Group 4 ¼ Patients who receive
b Symptom duration is the time (in days) that the patient had current symptoms for.
c Mean score of four items (burning, urgency, daytime frequency, night time frequen
between patients with symptom diary return information available vs. patients witho
between groups (p 0.359).considering the duration of moderately bad symptoms a negative
binomial model did not show signiﬁcant difference in recovery
between groups: incidence rate ratio (IRR) for Uva-ursi vs. placebo
1.02 (95% CI 0.72e1.45; p 0.922), and ibuprofen advice vs. no advice
IRR 0.87 (95% CI 0.62e1.24; p 0.453).Antibiotic use
Antibiotic use in the ﬁrst 2 weeks by participants (for whom
this information is available) is reported in Table 5. Overall
antibiotic use ranged considerably from 24 out of 70 (34.3%) in
Group 1 (Uva-ursi þ ibuprofen advice) to 42 out of 74 (56.8%) in
Group 4 (placebo þ no advice). For those receiving Uva-ursi use
was 57 out of 143 (39.9%) vs. 63 out of 133 (47.4%) and those
given ibuprofen advice 45 out of 129 (34.9%) vs. 75 out of 147
(51.0%). A logistic regression analysis for antibiotic use gave an
odds ratio (OR) 0.59 (95% CI 0.22e1.58; p 0.293) for Uva-ursi and
for ibuprofen OR 0.27 (95% CI 0.10e0.72; p 0.009) (Table 6).
Using the unadjusted data, one less woman would use antibi-
otics in the following 2 weeks for every 6.8 women given
ibuprofen advice (95% CI 4.2e18.0).Per protocol analysis
When analysed per protocol, the primary endpoint was unal-
tered (Table S2). The per protocol analysis on the ibuprofen related
per protocol population E (n ¼ 182 with complete data) for anti-
biotic use gave similar estimates for the odds ratios but the effect
was attenuated and no longer signiﬁcant for ibuprofen: Uva-ursi
odds ratio 0.81 (95% CI 0.22e3.01, p 0.756); ibuprofen OR 0.43
(95% CI 0.12e1.57, p 0.202) (Table S3).Re-consultation
Re-consultation data collected from notes review showed that
re-consulting with urinary tract infection symptoms was recorded
in 58 out of 382 (15.2%) in the ﬁrst month and 88 out of 382 (23.0%)
in the 3 months following the index consultation (Table 7). Logistic
regression analysis did not show any evidence of differences be-
tween the groups (data not shown).profen
)
Group 3a
(Uva-ursi þ No ibuprofen
advice) (n ¼ 97)
Group 4a
(Placebo þ No Ibuprofen
advice) (n ¼ 97)
Total (n ¼ 382)
44.6 (16.10) 44.8 (14.29) 43.8 (15.36)
4.0 (3.0 to 7.0) 4.0 (2.0 to 6.0) 3.0 (2.0 to 6.0)
36.7 (0.42) 36.8 (0.41) 36.7 (0.44)
23 (34.3%) 24 (32.4%) 92 (31.8%)
32 (50.0%) 34 (51.5%) 126 (53.2%)
97, 2.4 (1.13) 97, 2.4 (1.11) 382, 2.5 (1.15)
67, 2.5 (1.08) 69, 2.4 (1.16) 248, 2.4 (1.11)
30, 2.3 (1.23) 28, 2.5 (1.01) 134, 2.5 (1.22)
ients who received Uva-ursi placebo and advice to take ibuprofen, Group 3¼ Patients
d Uva-ursi placebo and no advice to take ibuprofen.
Information collected at baseline.
cy) as per primary outcome. t test comparing baseline frequency symptom score
ut symptom diary return information available identiﬁed no signiﬁcant difference
Table 2
Withdrawal information for the trial
Reason for withdrawal Group 1a
(uva-ursi þ ibuprofen
advice) (n ¼ 102)
Group 2a
(Placebo þ Ibuprofen
advice) (n ¼ 86)
Group 3a
(uva-ursi þ No
ibuprofen advice) (n ¼ 97)
Group 4a
(Placebo þ No
Ibuprofen advice) (n ¼ 97)
Total (n ¼ 382)
End of Study form present, n (%) 102 (100) 86 (100) 97 (100) 97 (100) 382 (100)
Completed study, n (%) 98 (96.1) 80 (93.0) 95 (97.9) 96 (99.0) 369 (96.6)
Did not complete study, n (%) 4 (3.9) 6 (7.0) 2 (2.1) 1 (1.0) 13 (3.4)
a Group 1, patients who received Uva-ursi and advice to take ibuprofen; Group 2, patients who received Uva-ursi placebo and advice to take ibuprofen; Group 3, patients
who received Uva-ursi and no advice to take ibuprofen; Group 4, patients who received Uva-ursi placebo and no advice to take ibuprofen.
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A pre-planned subgroup analysis for the primary endpoint
excluding those without evidence of infection on the urine culture
(with infection n ¼ 92) did not alter the inferences for symptom
severity (when adjusting for antibiotic use up to day 4): Uva-ursi
e0.17 (95% CI e0.64 to 0.30; p 0.476); ibuprofen 0.22 (95% CI
e0.29 to 0.73; p 0.401).
Harms
No episodes of upper tract infection were documented in any
group (for all patients 95% CI 0e0.00961). There were two SAEs
reported in trial participants, both were hospital admissions. The
ﬁrst episode was an abdominal wall abscess; this occurred in a
patient within the Uva-ursi and the no advice to take ibuprofen
group and was considered unlikely to be related to treatment. The
second was right iliac fossa pain; this occurred in a patient within
the Uva-ursi placebo and no advice to take ibuprofen group and
was not considered to be related to treatment.
Discussion
Summary of main ﬁndings
There was no evidence of differences between either Uva-ursi
vs. placebo or ibuprofen advice vs. no advice in terms of symp-
tom severity after 2e4 days (primary outcome). Antibiotic use was
a little lower than anticipated from previous studies where 77% of
those randomized to a ‘delayed prescription’ took their antibiotic
treatment. In this study (42/74) 56.8% of those in the control arm
took antibiotics in the ﬁrst 2 weeks. While the odds ratios suggestTable 3
Analysis of covariance of mean frequency symptom severity score on Days 2e4a (ITT pop
Characteristic Statistic
Primary comparison model (Uva-ursi versus no Uva-ursi e advice to take ibuprofe
Primary endpoints (least squares means) Estimate D
Group 1 þ 3b Uva-ursi (n ¼ 199) 1.83 e
Group 2 þ 4b Placebo (n ¼ 183) 1.89
Group 1 þ 2b Ibuprofen advice (n ¼ 188) 1.86 e
Group 3 þ 4b No advice (n ¼ 194) 1.87
Model coefﬁcients Estimate 9
Group 1 þ 3b e0.06 (
Group 2 þ 4b 0 (Ref) d
Group 1 þ 2b -0.01 (
Group 3 þ 4b 0 (Ref) d
Intercept 0.98 (
Frequency symptom severity at baseline 0.41 (
Age 0 (
The interaction effect between Uva-ursi and ibuprofen was not found to be signiﬁcant (
CI, conﬁdence interval; ANCOVA, analysis of covariance; LS means, least squares means.
a ANCOVA model, frequency mean symptom severity on Days 2e4 ¼ intercept þ trea
b Group 1 þ 3, patients who received Uva-ursi; Group 2 þ 4, patients who received Uv
3 þ 4, patients who received no advice to take ibuprofen.substantial reduction in antibiotic use for both Uva-ursi (0.59; 95%
CI 0.22e1.58) and ibuprofen advice (0.27; 95% CI 0.10e0.72) for
Uva-ursi the conﬁdence intervals were wide and the results did not
reach statistical signiﬁcance. There were no episodes of upper tract
infection and only two serious adverse events.
Strengths and limitations
This is a large study in primary care recruiting women pre-
senting with typical symptoms of urinary tract infection in whom
the majority in usual care would usually be treated with antibiotic
therapy. Older women were excluded because urinary infection is
common but the precise diagnosis becomes less certain, so the
results cannot be generalized to an older population. Women who
met the existing cautions or contra-indications to ibuprofen (which
include asthma) were not included hence limiting the ability to test
the Uva-ursi which had no such restrictions in a wider group. The
maximum quoted dose of ibuprofen is 2400 mg per day; however,
in clinical practice lower doses are usually offered. We used the
dose which is commonly recommended and was used for UTIs in
previous studies. It is plausible that higher doses may have resulted
in more symptom response. Follow-up data were limited, with 248
out of 382 patients (35%) missing some primary endpoint infor-
mation, hence potentially reducing the internal validity of the trial;
however, analysis using all participants and multiple imputation
should largely account for this deﬁciency. Moreover the inferences
were unchanged in the per protocol analysis.
Comparison with literature
The conﬁrmed frequency of urine infection (32%) was low
compared with previous studies using similar entry criteria but thisulation B, n ¼ 382)
n versus no advice to take ibuprofen)
ifference 95% CI of LS mean Two-sided p
0.06 (e0.33, 0.21) 0.661
0.01 (e0.27, 0.26) 0.951
5% CI Two-sided p
e0.33, 0.21) 0.661
d
e0.27, 0.26) 0.951
d
0.40, 1.57) <0.001
0.29, 0.53) <0.001
e0.01, 0.01) 0.636
p 0.803).
tment group þ frequency mean symptom severity at baseline þ age.
a-ursi placebo; Group 1 þ 2, patients who received advice to take ibuprofen; Group
Table 4
Analysis of covariance of mean frequency symptom severity score on Days 2e4a controlling for antibiotic use (ITT population B, n ¼ 382)
Characteristic Statistic
Comparison Model (Uva-ursi versus no Uva-ursi e advice to take ibuprofen versus no advice to take ibuprofen, controlling for antibiotic use)
Least squares means Estimate Difference 95% CI of LS Mean Two-sided pa
Group 1 þ 3b Uva-ursi (n ¼ 199) 1.92 e0.05 (e0.32, 0.21) 0.704
Group 2 þ 4b Placebo (n ¼ 183) 1.97
Group 1 þ 2b Ibuprofen advice (n ¼ 188) 1.97 0.04 (e0.24, 0.31) 0.791
Group 3 þ 4b No advice (n ¼ 194) 1.93
Model coefﬁcients Estimate 95% CI p
Group 1 þ 3b -0.05 (e0.32, 0.21) 0.704
Group 2 þ 4b 0 (Ref) d d
Group 1 þ 2b 0.04 (e0.24, 0.31) 0.791
Group 3 þ 4b 0 (Ref) d d
Intercept 0.86 (0.32, 1.41) 0.002
Frequency symptom severity at baseline 0.41 (0.30, 0.53) <0.001
Antibiotic use up to Day 4 e Yes 0.31 (0.02, 0.60) 0.033
Antibiotic use up to Day 4 e No 0 (Ref) d d
Age 0 (e0.01, 0.01) 0.672
The interaction effect between Uva-ursi and ibuprofen was not found to be signiﬁcant (p 0.782).
CI, conﬁdence interval; ANCOVA, analysis of covariance; LS means, least squares means.
a ANCOVAmodel: Frequency mean symptom severity on Days 2e4, intercept þ treatment group þ frequency mean symptom severity at baseline þ age þ antibiotic use up
to Day 4.
b Group 1 þ 3, patients who received Uva-ursi; Group 2 þ 4, patients who received Uva-ursi placebo; Group 1 þ 2, patients who received advice to take ibuprofen; Group
3 þ 4, patients who received no advice to take ibuprofen.
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a more recent study (POETIC) using similar entry criteria showed
comparable frequencies [4,14,16,17]. Despite the low frequency of
conﬁrmed infection in routine care the majority of womenwill still
receive antibiotics (90%) and so these results are still generalizable
to the majority of women presenting [17]. In terms of symptom
severity at recruitment, it would be anticipated that those agreeing
to participate (and accepting a delayed prescription) might have
less severe symptoms; this appears to be the case. In two compa-
rable trials in urine infection the simple sum (SD) of three fre-
quency items (urgency, daytime frequency, and night time
frequency) was 9.6 (3.7) (information from authors) [13] and 9.5
respectively [17]. In comparison, in this study the sum of these
three frequency items was 7.5 (3.8). The inclusion of women with
less severe symptoms may limit the ability of the diary to
demonstrate change during recovery although an analysis of those
with more severe symptoms still showed no effect on symptoms
despite maintaining the effect on antibiotics.
A major concern over withholding of antibiotics is the potential
for progressive infection and upper urinary tract infection. All threeTable 5
Summary of use of antibiotics (ITT population A, n ¼ 382)
Characteristic Group 1a
(uva-ursi þ ibuprofen
advice) (n ¼ 102)
Group 2a
(Placebo þ Ibuprofen
advice) (n ¼ 86)
Group 3a
(uva-ursi þ No
ibuprofen advice)
(n ¼ 97)
G
(
I
(
Use of antibiotics at
any time during
Week 1, n (%)
17 (24.3) 21 (35.6) 33 (45.2) 4
Use of antibiotics at
any time during
Week 1 and
Week 2, n (%)
24 (34.3) 21 (35.6) 33 (45.2) 4
Use of antibiotics as
recorded in the
medical notes
review, n (%)c
21 (77.8) 15 (83.3) 22 (91.7) 2
a Group 1, patients who received Uva-ursi and advice to take ibuprofen; Group 2, pati
who received Uva-ursi and no advice to take ibuprofen; Group 4, patients who received
b Group 1 þ 3, patients who received Uva-ursi; Group 2 þ 4, patients who received Uv
3 þ 4, patients who received no advice to take ibuprofen.
c This is any re-consultation with urinary tract infection symptoms after the initial costudies of NSAID in UTI reported an excess of pyelonephritis in the
NSAID arm compared with antibiotic [9e11]. In contrast, no epi-
sodes of upper tract infection were reported in this study. It is
possible that this difference is explained by the design in which all
participants were provided with back-up antibiotics and thus those
with progressive symptoms had the option for prompt self-
management. It is also plausible that the women selected for
recruitment in the current study with less severe symptoms at
study entry were also at lower risk of subsequent upper tract
infection.
Implications for practice
In this study we were able to demonstrate a substantial reduc-
tion in antibiotic use compared with usual care with no reported
episodes of upper tract infection. We were not able to demonstrate
superiority of either intervention over placebo in terms of symptom
relief or speed of recovery. Although the results are consistent with
reduced antibiotic consumption when active symptom relief is
provided (Uva-ursi) or recommended (ibuprofen), this result onlyroup 4a
Placebo þ No
buprofen advice)
n ¼ 97)
Group 1þ3b
(uva ursi)
(n ¼ 199)
Group 2þ4b
(Placebo)
(n ¼ 183)
Group 1þ2b
(Ibuprofen
advice)
(n ¼ 188)
Group 3þ4b
(No advice)
(n ¼ 194)
Total
(n ¼ 382)
1 (55.4) 50 (35.0) 62 (46.6) 38 (29.5) 74 (50.3) 112 (40.6)
2 (56.8) 57 (39.9) 63 (47.4) 45 (34.9) 75 (51.0) 120 (43.5)
3 (85.2) 43 (84.3) 38 (84.4) 36 (80.0) 45 (88.2) 81 (84.4)
ents who received Uva-ursi placebo and advice to take ibuprofen; Group 3, patients
Uva-ursi placebo and no advice to take ibuprofen.
a-ursi placebo; Group 1 þ 2, patients who received advice to take ibuprofen; Group
nsultation as recorded in the 3 month data.
Table 6
Logistic regression model results for use of antibiotics during Week 1 and Week 2 (ITT population A, n ¼ 382 (276)a)
Characteristic Estimate SE Two-sided p
Intercept 0.24 0.47 0.616
Group 1 (Uva-ursi þ Ibuprofen) e0.92 0.34 0.007
Group 2 (Uva-ursi placebo þ Ibuprofen) e0.86 0.36 0.018
Group 3 (Uva-ursi þ Ibuprofen placebo) e0.46 0.33 0.162
Group 4 (Uva-ursi placebo þ Ibuprofen placebo) 0 (Ref) d d
Age 0.0007 0.01 0.934
Comparison Odds ratiob 95% CI Two-sided p
Group: 1 þ 3 vs. 2 þ 4c (Uva ursi vs. placebo) 0.59 (0.22 to 1.58) 0.293
Group: 1 þ 2 vs. 3 þ 4c (Ibuprofen advice vs. no advice) 0.27 (0.10 to 0.72) 0.009
SE, standard error; CI, conﬁdence interval.
a Population A consist of 382 patients, of which 276 patients had complete information and were included in the logistic regression analysis.
b Odds ratios above 1 represent a favourable outcome for the ﬁrst category in the comparison.
c Group 1 þ 3, patients who received Uva-ursi; Group 2 þ 4, patients who received Uva-ursi placebo; Group 1 þ 2, patients who received advice to take ibuprofen; Group
3 þ 4, Patients who received no advice to take ibuprofen.
Table 7
Re-consultation with urinary tract infection e from diary data (ITT population A, n ¼ 382)
Group 1a (Uva-ursi þ ibuprofen
advice) (n ¼ 102)
Group 2a Placebo þ Ibuprofen
advice (n ¼ 86)
Group 3a Uva-ursi þ No
ibuprofen advice (n ¼ 97)
Group 4a Placebo þ No
Ibuprofen advice (n ¼ 97)
Total (n ¼ 382)
Re-consultation with
symptoms of UTI
within one month as
recorded in the three
month medical notes
review, n (%)
15 (14.7) 11 (12.8) 16 (16.5) 16 (16.5) 58 (15.2)
Re-consultation with
symptoms of UTI
within three months
as recorded in the
three month medical
notes review, n (%)
23 (22.5) 16 (18.6) 22 (22.7) 27 (27.8) 88 (23.0)
a Group 1, patients who received Uva-ursi and advice to take ibuprofen; Group 2, patients who received Uva-ursi placebo and advice to take ibuprofen; Group 3, patients
who received Uva-ursi and no advice to take ibuprofen; Group 4, patients who received Uva-ursi placebo and no advice to take ibuprofen.
M. Moore et al. / Clinical Microbiology and Infection 25 (2019) 973e980 979reached statistical signiﬁcance for ibuprofen. Use of a delayed
prescription in tandem with advice to take ibuprofen is a good
option for women with less severe urinary symptoms and willing to
delay antibiotic use based on current evidence and is likely to result
in substantial reduction in antibiotic use compared to usual care.
Transparency declaration
The lead author (the manuscript's guarantor) afﬁrms that the
manuscript is an honest, accurate, and transparent account of the
study being reported; that no important aspects of the study have
been omitted; and that any discrepancies from the study as plan-
ned (and, if relevant, registered) have been explained. This paper
presents independent research funded by the National Institute for
Health Research School for Primary Care Research (NIHR SPCR). The
views expressed are those of the author(s) and not necessarily
those of the NIHR, the NHS or the Department of Health. All authors
have completed the ICMJE uniform disclosure form at http://www.
icmje.org/coi_disclosure.pdf and declare: no support from any or-
ganization for the submitted work; no ﬁnancial relationships with
any organizations including industry that might have an interest in
the submitted work in the previous three years, no other re-
lationships or activities that could appear to have inﬂuenced the
submitted work. This project is funded by the National Institute for
Health Research (NIHR) School of Primary Care, project number
170. The project is sponsored by the University of Southampton.
Relevant anonymized patient level data available after approval of
the proposal andwith a data sharing agreement. The study protocolhas been published. Statistical analysis plan and consent form will
be published on the institution repository.
Acknowledgements
An independent Trial Steering Committee oversaw the running
of the trial (chair Stephen Falk) and an Independent Data Moni-
toring Committee comprised Professor Kerry Hood (chair), Dr Nick
Francis and Dr Julie Whitehouse reviewed the data during the
running of the trials. Professor George Lewith made a signiﬁcant
contribution to the application for funding, development of the
protocol and trial oversight but sadly died before the full results
were available. We are grateful to our patient contributor Linda
Hammick who helped throughout the study design, management
and interpretation. We are also grateful to Essential Nutrition who
received the imported raw materials, completed encapsulation,
preparation of the placebo, randomization storage and distribution.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.cmi.2019.01.011.
References
[1] Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and
economic costs. Am J Med 2002;113:5Se13S.
[2] Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al. Presen-
tation, pattern, and natural course of severe symptoms, and role of antibiotics
M. Moore et al. / Clinical Microbiology and Infection 25 (2019) 973e980980and antibiotic resistance among patients presenting with suspected uncom-
plicated urinary tract infection in primary care: observational study. BMJ
2010;340:b5633.
[3] Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus
placebo in the treatment of women with uncomplicated cystitis: a meta-
analysis of randomized controlled trials. J Infect 2009;58:91e102. https://
doi.org/10.1016/j.jinf.2008.12.009.
[4] Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al. Presen-
tation, pattern, and natural course of severe symptoms, and role of antibiotics
and antibiotic resistance among patients presenting with suspected uncom-
plicated urinary tract infection in primary care: observational study. BMJ
2010:340. https://doi.org/10.1136/bmj.b5633.
[5] Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:
653e60. https://doi.org/10.1038/nrurol.2010.190.
[6] Leydon G, Turner S, Smith H, Little P. Women's views about management and
cause of urinary tract infection: qualitative interview study. BMJ 2010;340.
https://doi.org/10.1136/bmj.c279.
[7] Leydon G, Turner S, Smith H, Little P. The journey from self-care to GP care: a
qualitative interview study of women presenting with symptoms of urinary
tract infection. Br J Gen Pract 2009;59:e219e25.
[8] Trill J, Simpson C, Webley F, Radford M, Stanton L, Maishman T, et al. Uva-ursi
extract and ibuprofen as alternative treatments of adult female urinary tract
infection (ATAFUTI): study protocol for a randomised controlled trial. Trials
2017;18:421. https://doi.org/10.1186/s13063-017-2145-7.
[9] Gagyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-
Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract
infection in women: randomised controlled trial. BMJ 2015;351:h6544.
https://doi.org/10.1136/bmj.h6544 [published Online First: 2015/12/25].
[10] Kronenberg A, Butikofer L, Odutayo A, Muhlemann K, da Costa BR, Battaglia M,
et al. Symptomatic treatment of uncomplicated lower urinary tract infectionsin the ambulatory setting: randomised, double blind trial. BMJ 2017;359:
j4784. https://doi.org/10.1136/bmj.j4784.
[11] Vik I, Bollestad M, Grude N, Barheim A, Damsgaard E, Neumark T, et al.
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in
women-A double-blind, randomized non-inferiority trial. PLoS Med 2018;15,
e1002569.
[12] Bleidorm J, Gagyor I, Kochen M, Wegscheider K, Hummers-Pradie E. Symp-
tomatic treatment (ibuprofen) or antibiotics (ciproﬂoxacin) for uncomplicated
urinary tract infection? - results of a randomized controlled pilot trial. BMC
Med 2010;8:30.
[13] Little P, Moore M, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effec-
tiveness of ﬁve different approaches in management of urinary tract infec-
tion: randomised controlled trial. Br Med J 2010;340. https://doi.org/
10.1136/bmj.c199.
[14] Bates J, Thomas-Jones E, Pickles T, Kirby N, Gal M, Bongard E, et al. Point of
care testing for urinary tract infection in primary care (POETIC): protocol for a
randomised controlled trial of the clinical and cost effectiveness of FLEXICULT
informed management of uncomplicated UTI in primary care. BMC Fam Pract
2014;15:187. https://doi.org/10.1186/s12875-014-0187-4.
[15] Watson L, Little P, Moore M, Warner G, Williamson I. Validation study of a
diary for use in acute lower respiratory tract infection. Fam Pract 2001;18:
553e4.
[16] Aspevall O, Hallander H, Gant V, Kouri T. European guidelines for urinalysis: a
collaborative document produced by European clinical microbiologists and
clinical chemists under ECLM in collaboration with ESCMID. Clin Microbiol
Infect 2001;7:173e8.
[17] Butler CC, Francis N, Thomas-Jones E, Llor C, Bongard E, Moore M, et al.
Variations in presentation, management, and patient outcomes of urinary
tract infection: a prospective four-country primary care observational cohort
study. Br J Gen Pract 2017. https://doi.org/10.3399/bjgp17X693641.
